ANI Pharmaceuticals Inc.

33.03+0.6400+1.98%Vol 49.82K1Y Perf -33.63%
Apr 13th, 2021 16:00 DELAYED
BID33.05 ASK33.10
Open32.17 Previous Close32.39
Pre-Market- After-Market33.03
 - -  - -%
Target Price
42.67 
Analyst Rating
Moderate Buy 2.00
Potential %
29.19 
Finscreener Ranking
★★+     49.18
Insiders Trans % 3/6/12 mo.
100/100/100 
Value Ranking
★★     46.15
Insiders Value % 3/6/12 mo.
100/100/100 
Growth Ranking
★★     45.60
Insiders Shares Cnt. % 3/6/12 mo.
100/100/100 
Income Ranking
 —    -
Market Cap408.42M 
Earnings Rating
Strong Sell
Price Range Ratio 52W %
33.07 
Earnings Date
6th May 2021

Today's Price Range

31.6933.25

52W Range

23.5552.22

5 Year PE Ratio Range

-410.20213.40

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
2.80%
1 Month
2.13%
3 Months
2.90%
6 Months
13.90%
1 Year
-33.63%
3 Years
-44.51%
5 Years
-23.36%
10 Years
-55.68%

TickerPriceChg.Chg.%
ANIP33.030.64001.98
AAPL134.433.19002.43
GOOG2 267.2712.48000.55
MSFT258.312.40000.94
XOM55.710.21000.38
WFC39.79-0.9800-2.40
JNJ159.48-2.1600-1.34
FB309.76-1.7800-0.57
GE13.44-0.1500-1.10
JPM154.09-1.8600-1.19
Financial StrengthValueIndustryS&P 500US Markets
1.30
2.20
0.47
0.95
-1.70
Leverage Ratio 2.40
ProfitabilityValueIndustryS&P 500US Markets
58.20
-7.90
13.50
3.00
-9.64
RevenueValueIndustryS&P 500US Markets
158.70M
12.85
3.62
20.28
Earnings HistoryEstimateReportedSurprise %
Q04 20200.850.65-23.53
Q03 20200.780.813.85
Q02 20200.570.55-3.51
Q01 20200.760.8917.11
Q04 20191.020.93-8.82
Q03 20191.321.07-18.94
Q02 20191.181.288.47
Q01 20191.031.3026.21
Earnings Per EndEstimateRevision %Trend
3/2021 QR0.58-27.50Negative
6/2021 QR0.66-26.67Negative
12/2021 FY2.87-18.00Negative
12/2022 FY4.37-22.52Negative
Next Report Date6th May 2021
Estimated EPS Next Report0.58
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume49.82K
Shares Outstanding12.37M
Trades Count989
Dollar Volume1.97M
Avg. Volume57.75K
Avg. Weekly Volume52.95K
Avg. Monthly Volume67.61K
Avg. Quarterly Volume56.34K

ANI Pharmaceuticals Inc. (NASDAQ: ANIP) stock closed at 33.03 per share at the end of the most recent trading day (a 1.98% change compared to the prior day closing price) with a volume of 49.82K shares and market capitalization of 408.42M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 338 people. ANI Pharmaceuticals Inc. CEO is Nikhil Lalwani.

The one-year performance of ANI Pharmaceuticals Inc. stock is -33.63%, while year-to-date (YTD) performance is 13.74%. ANIP stock has a five-year performance of -23.36%. Its 52-week range is between 23.55 and 52.22, which gives ANIP stock a 52-week price range ratio of 33.07%

ANI Pharmaceuticals Inc. currently has a PE ratio of -17.00, a price-to-book (PB) ratio of 2.02, a price-to-sale (PS) ratio of 2.48, a price to cashflow ratio of 25.00, a PEG ratio of 2.32, a ROA of -4.70%, a ROC of -4.12% and a ROE of -10.55%. The company’s profit margin is -9.64%, its EBITDA margin is 13.50%, and its revenue ttm is $158.70 Million , which makes it $12.85 revenue per share.

Of the last four earnings reports from ANI Pharmaceuticals Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $0.58 for the next earnings report. ANI Pharmaceuticals Inc.’s next earnings report date is 06th May 2021.

The consensus rating of Wall Street analysts for ANI Pharmaceuticals Inc. is Moderate Buy (2), with a target price of $42.67, which is +29.19% compared to the current price. The earnings rating for ANI Pharmaceuticals Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

ANI Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

ANI Pharmaceuticals Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 6.03, ATR14 : 1.53, CCI20 : -28.39, Chaikin Money Flow : -0.05, MACD : 0.15, Money Flow Index : 54.41, ROC : 5.16, RSI : 56.33, STOCH (14,3) : 35.80, STOCH RSI : 1.00, UO : 50.69, Williams %R : -64.20), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of ANI Pharmaceuticals Inc. in the last 12-months were: Patrick D. Walsh (Buy at a value of $693 065)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
1 (33.33 %)
1 (33.33 %)
2 (66.67 %)
Moderate Buy
1 (33.33 %)
1 (33.33 %)
1 (33.33 %)
Hold
1 (33.33 %)
1 (33.33 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
2.00
Moderate Buy
2.00
Strong Buy
1.33

ANI Pharmaceuticals Inc.

ANI Pharmaceuticals Inc develops, manufactures and markets generic prescription pharmaceuticals, made in the U.S.A. It manufactures liquid, powder and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Its generic products include Erythromycin Ethylsuccinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Flecainide, Fluvoxamine, Hydrocortisone Enema, Methazolamide, Metoclopramide Syrup Nilutamide, Nimodipine, Opium Tincture, Oxycodone Capsules, Oxycodone Oral Solution, Propafenone, and Vancomycin.

CEO: Nikhil Lalwani

Telephone: +1 218 634-3500

Address: 210 Main Street West, Baudette 56623, MN, US

Number of employees: 338

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

44%56%

Bearish Bullish

70%30%

Bearish Bullish

48%52%

News

Stocktwits